Shilpa Medicare has unveiled its innovative hybrid CDMO model at DCAT 2025, offering comprehensive discovery, clinical, and commercial outsourcing services. This new approach allows the company to serve both small and large molecule customers, with a strong focus on oncology and peptides.

A key feature of this model is its dual-service approach, which includes custom CDMO partnerships and off-the-shelf novel formulations for exclusive B2B licensing. This enables pharmaceutical companies to either collaborate with Shilpa for development or license fully developed products, reducing risk and expediting market entry. Currently, the CDMO has multiple assets in its pipeline and three late-stage products available for licensing.

With five R&D centers and six state-of-the-art manufacturing facilities, Shilpa Medicare is well-positioned to capitalize on the growing demand for pharmaceutical outsourcing to India. The company offers advanced formulation technologies like nano liposomes, liquid-lyophilization, and microfluidization, along with large-scale manufacturing capabilities for biologics, peptides, and high-potency compounds.

Boasting a talent pool of over 3,000 professionals, including 350+ scientists, Shilpa continues to expand its global partnerships. With approvals from major regulators like US FDA, EMA, and PMDA, the company is set to sign significant deals at DCAT, reinforcing its position as a leading full-service CDMO.